Xenon Pharmaceuticals Executive Compensation (FY25)
XENE · Executive and director compensation, fiscal 2025 only
The Xenon Pharmaceuticals brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 7, 2026Latest filing (8-K): June 3, 2026
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
187 figures on this page: 180 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
Frequently asked questions
Answers drawn from the data on this page.
Who is Xenon Pharmaceuticals' chief executive and what were they paid?
Ian Mortimer was paid $9,221,712 in total compensation as President and Chief Executive Officer for fiscal 2025.
What was Xenon Pharmaceuticals' say-on-pay result?
The say-on-pay proposal drew 94.5% of votes cast for or against in favor at the meeting held June 2, 2026 for fiscal 2025.
Which companies are in Xenon Pharmaceuticals' peer group?
The disclosed peer group names Agios Pharmaceuticals Inc., Apellis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Aurinia Pharmaceuticals Inc. and Avidity Biosciences, Inc., among others.
What is Xenon Pharmaceuticals' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 37:1, against median employee compensation of $246,438.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Ian Mortimer President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Thomas Kelly Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Darren Cline Chief Commercial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Christopher Kenney Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Andrea DiFabio Chief Legal Officer and Corporate Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Sherry Aulin Former Chief Financial Officer Departed during or after this year | ◇ | ◇ | — | — | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Andrea DiFabio | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Andrea DiFabio | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Christopher Kenney | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Christopher Kenney | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Darren Cline | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Ian Mortimer | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Ian Mortimer | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Thomas Kelly | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Thomas Kelly | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Andrea DiFabio | PSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 3/10/2034 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/9/2033 | |
| Option | ◇ | — | ◇ | 11/6/2032 | |
| Option | ◇ | — | ◇ | 3/11/2035 | |
| Christopher Kenney | Option | ◇ | — | ◇ | 3/10/2034 |
| Option | ◇ | — | ◇ | 3/11/2035 | |
| Option | ◇ | — | ◇ | 3/9/2033 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Ian Mortimer | Option | ◇ | — | ◇ | 3/11/2035 |
| Option | ◇ | — | ◇ | 3/10/2034 | |
| Option | ◇ | — | ◇ | 3/9/2033 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Thomas Kelly | Option | ◇ | — | ◇ | 10/14/2035 |
| PSU | ◇ | ◇ | — | — | |
| Darren Cline | PSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 6/22/2035 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Andrea DiFabio
Chief Legal Officer and Corporate Secretary · Employment agreement · citing a 2026 filing
| Severance base | ◇ |
Darren Cline
Chief Commercial Officer · Offer letter
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Ian Mortimer
President and Chief Executive Officer · Employment agreement · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Equity acceleration on change in control | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Sherry Aulin
Former Chief Financial Officer
| Change-in-control trigger | ◇ |
Thomas Kelly
Chief Financial Officer · Employment agreement
| Equity acceleration on change in control | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Dawn Svoronos Board chair | ◇ | ◇ | ◇ | — | — | — | ◇ |
Justin Gover | ◇ | ◇ | ◇ | — | — | — | ◇ |
Steven Gannon | ◇ | ◇ | ◇ | — | — | — | ◇ |
Patrick Machado | ◇ | ◇ | ◇ | — | — | — | ◇ |
Gary Patou | ◇ | ◇ | ◇ | — | — | — | ◇ |
Elizabeth Garofalo | ◇ | ◇ | ◇ | — | — | — | ◇ |
Gillian Cannon | ◇ | ◇ | ◇ | — | — | — | ◇ |
Ian Mortimer served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee member | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options and/or RSUs.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Agios Pharmaceuticals Inc. AGIO
- Apellis Pharmaceuticals, Inc. APLS
- Arrowhead Pharmaceuticals, Inc. ARWR
- Aurinia Pharmaceuticals Inc. AUPH
- Avidity Biosciences, Inc. RNAM
- Axsome Therapeutics, Inc. AXSM
- Biohaven Ltd. BHVN
- Crinetics Pharmaceuticals, Inc. CRNX
- Cytokinetics CYTK
- Day One Biopharmaceuticals, Inc. DAWN
- Denali Therapeutics Inc. DNLI
- ImmunityBio, Inc. IBRX
- Immunovant, Inc. IMVT
- Iovance Biotherapeutics, Inc. IOVA
- Madrigal Pharmaceuticals, Inc. MDGL
- Revolution Medicines, Inc. RVMD
- Scholar Rock Holding Corporation SRRK
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 2, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 4, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 4, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 1, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 1, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 3, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | June 1, 2020 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Xenon Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Xenon Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
187 figures on this page: 180 cited to the filing that reported them, 7 calculated from figures it prints.
180 cited to the filing
7 calculated from the filing
Documents cited
- 0001193125-26-255396Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-26-170320CEO Pay Ratio · Exhibit · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal Year-End · and 2 more sections
- 0000950170-25-082494Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-25-029149Exhibit
- 0000950170-24-069318Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-23-026070Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-22-022228Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-21-031608Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-20-028137Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-26-076650Exhibit
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Xenon Pharmaceuticals executive compensation, FY2025.” https://intel.velarion.ai/comp/XENE (accessed 2026).
Short form: data: Velarion
The Xenon Pharmaceuticals brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Xenon Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Xenon Pharmaceuticals discloses
The companies named in XENE's own disclosed peer group.
Agios Pharmaceuticals Inc.Apellis Pharmaceuticals, Inc.Arrowhead Pharmaceuticals, Inc.Aurinia Pharmaceuticals Inc.Axsome Therapeutics, Inc.Biohaven Ltd.Crinetics Pharmaceuticals, Inc.CytokineticsDay One Biopharmaceuticals, Inc.Denali Therapeutics Inc.ImmunityBio, Inc.Immunovant, Inc.Iovance Biotherapeutics, Inc.Madrigal Pharmaceuticals, Inc.Revolution Medicines, Inc.Scholar Rock Holding Corporation
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}